TrialNature medicine2026

Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial.

Atul Malhotra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.